Clinical Trials
1
Active:0
Completed:0
Trial Phases
1 Phases
Phase 4:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
Phase 4
1 (100.0%)Optimal Antithrombotic Therapy in Ischemic Stroke Patients with Non-Valvular Atrial Fibrillation and Atherothrombosis
Phase 4
Terminated
- Conditions
- Ischemic StrokeAtherothrombosisAtrial Fibrillation
- Interventions
- Drug: Oral AnticoagulantDrug: Antiplatelet Drug
- First Posted Date
- 2017-02-23
- Last Posted Date
- 2024-12-27
- Target Recruit Count
- 321
- Registration Number
- NCT03062319
- Locations
- 🇯🇵
National Hospital Organization Osaka National Hospital, Osaka, Japan
News
Ono Pharma to Present Positive Phase 2 Data for Tirabrutinib in PCNSL and ONO-4578 in Rectal Cancer at ASCO 2025
Ono Pharmaceutical will present positive results from the Phase 2 PROSPECT study of tirabrutinib for relapsed or refractory primary central nervous system lymphoma at ASCO 2025 in Chicago.